Skip to Content

Otezla (apremilast) Disease Interactions

There are 3 disease interactions with Otezla (apremilast):


Apremilast (Includes Otezla) ↔ Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression

Apremilast therapy has been associated with adverse reactions of depression. During controlled clinical trials, 1.0% of patients treated with apremilast reported depression or depressed mood compared to 0.8% of those receiving placebo. Furthermore, 0.3% in the apremilast group discontinued treatment due to depression or depressed mood and 0.2% experienced suicidal ideation or behavior, compared to none in the placebo group. By contrast, two patients in the placebo group committed suicide versus none in the apremilast group. Therapy with apremilast should be administered cautiously in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the potential for emergence or worsening of depression, suicidal thoughts or other mood changes, and to contact the physician if such changes occur. The need for continued treatment with apremilast should be carefully weighed against the risks.


Apremilast (Includes Otezla) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Increased apremilast systemic exposure has been observed in patients with severe renal impairment (CrCl < 30 mL/min). Therapy with apremilast should be administered cautiously in these patients. Initial dosage titration and maintenance dosage should be reduced in accordance with the product package labeling.


Apremilast (Includes Otezla) ↔ Weight Loss

Moderate Potential Hazard, High plausibility

Applies to: Malnourished, Anorexia/Feeding Problems, Weight Loss/Failure to Thrive

Apremilast therapy has been associated with weight loss. During controlled clinical trials, weight reduction between 5% to 10% of body weight was reported in 10% of patients treated with apremilast compared to 3.3% of those receiving placebo. Weight change should be monitored during apremilast therapy, particularly in patients suffering from anorexia, malnutrition, or excessive weight loss. Physicians should evaluate any unexplained or clinically significant weight loss, and discontinuation of apremilast considered.

Otezla (apremilast) drug Interactions

There are 69 drug interactions with Otezla (apremilast)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.